FDA Advisory Panel Recommends Approval of Moderna’s Covid Vaccine By

© Reuters — An advisory panel to the Food and Drug Administration recommends approval of Moderna Inc (NASDAQ:)’s Covid-19 drug, clearing the way for the agency to approve the second vaccine to fight the pandemic.

The move, coming a week after the approval of a vaccine developed by Pfizer Inc (NYSE:) and BioNTech SE (NASDAQ:), marks a critical point in the battle with coronavirus. Vaccinations started this week across the United States, with front-line medical personnel getting first priority. Vice President Mike Pence and his wife are scheduled to receive the vaccine Friday morning.

Shares of Moderna traded up 5% during Thursday’s session in anticipation of the panel’s decision. Shares fell 3% in after-market hours.

Cities and states across the country are struggling to handle the economic toll of the pandemic against a grim daily record count of new cases and deaths.

The FDA could approve Moderna’s vaccine for emergency use as early as Friday, opening the possibility that its vaccine could start being injected next week.

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

Source link

Show More

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button